These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 17634538)

  • 1. TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid.
    Sørensen NM; Byström P; Christensen IJ; Berglund A; Nielsen HJ; Brünner N; Glimelius B
    Clin Cancer Res; 2007 Jul; 13(14):4117-22. PubMed ID: 17634538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of predictive markers for patients with advanced colorectal cancer.
    Byström P; Berglund Å; Nygren P; Wernroth L; Johansson B; Larsson A; Glimelius B
    Acta Oncol; 2012 Sep; 51(7):849-59. PubMed ID: 22974092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in soluble CEA and TIMP-1 levels during adjuvant chemotherapy for stage III colon cancer.
    Aldulaymi B; Christensen IJ; Sölétormos G; Jess P; Nielsen SE; Brünner N; Nielsen HJ
    Anticancer Res; 2010 Jan; 30(1):233-7. PubMed ID: 20150641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
    Li YH; An X; Xiang XJ; Wang ZQ; Wang FH; Feng F; Jiang WQ; He YJ; Xu RH
    Ai Zheng; 2009 Sep; 28(9):939-44. PubMed ID: 19728911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer.
    Frederiksen C; Qvortrup C; Christensen IJ; Glimelius B; Berglund A; Jensen BV; Nielsen SE; Keldsen N; Nielsen HJ; Brünner N; Pfeiffer P
    Ann Oncol; 2011 Feb; 22(2):369-75. PubMed ID: 20643864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial.
    Yoshino T; Obermannová R; Bodoky G; Garcia-Carbonero R; Ciuleanu T; Portnoy DC; Kim TW; Hsu Y; Ferry D; Nasroulah F; Tabernero J
    Eur J Cancer; 2017 Jun; 78():61-69. PubMed ID: 28412590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
    Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High plasma TIMP-1 and serum CEA levels during combination chemotherapy for metastatic colorectal cancer are significantly associated with poor outcome.
    Aldulaymi B; Byström P; Berglund A; Christensen IJ; Brünner N; Nielsen HJ; Glimelius B
    Oncology; 2010; 79(1-2):144-9. PubMed ID: 21150229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma TIMP-1 and CEA as Markers for Detection of Primary Colorectal Cancer: A Prospective Validation Study Including Symptomatic and Non-symptomatic Individuals.
    Christensen IJ; Brünner N; Dowell B; Davis G; Nielsen HJ; Newstead G; King D
    Anticancer Res; 2015 Sep; 35(9):4935-41. PubMed ID: 26254391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.
    Hamaguchi T; Denda T; Kudo T; Sugimoto N; Ura T; Yamazaki K; Fujii H; Kajiwara T; Nakajima TE; Takahashi S; Otsu S; Komatsu Y; Nagashima F; Moriwaki T; Esaki T; Sato T; Itabashi M; Oki E; Sasaki T; Chiron M; Yoshino T
    Cancer Sci; 2019 Nov; 110(11):3565-3572. PubMed ID: 31520559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
    Akbulut H; Altuntas F; Akbulut KG; Ozturk G; Cindoruk M; Unal E; Icli F
    Cytokine; 2002 Nov; 20(4):184-90. PubMed ID: 12543084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.
    Weihrauch MR; Ansén S; Jurkiewicz E; Geisen C; Xia Z; Anderson KS; Gracien E; Schmidt M; Wittig B; Diehl V; Wolf J; Bohlen H; Nadler LM
    Clin Cancer Res; 2005 Aug; 11(16):5993-6001. PubMed ID: 16115944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel prognostic index in colorectal cancer defined by serum carcinoembryonic antigen and plasma tissue inhibitor of metalloproteinases-1.
    Nielsen HJ; Christensen IJ; Brünner N
    Scand J Gastroenterol; 2010; 45(2):200-7. PubMed ID: 20095885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer.
    Ji SH; Park YS; Lee J; Lim DH; Park BB; Park KW; Kang JH; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Im YH; Kang WK; Park K
    Jpn J Clin Oncol; 2005 Apr; 35(4):214-7. PubMed ID: 15845571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
    Falcone A; Ricci S; Brunetti I; Pfanner E; Allegrini G; Barbara C; Crinò L; Benedetti G; Evangelista W; Fanchini L; Cortesi E; Picone V; Vitello S; Chiara S; Granetto C; Porcile G; Fioretto L; Orlandini C; Andreuccetti M; Masi G;
    J Clin Oncol; 2007 May; 25(13):1670-6. PubMed ID: 17470860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer.
    Schrohl AS; Meijer-van Gelder ME; Holten-Andersen MN; Christensen IJ; Look MP; Mouridsen HT; Brünner N; Foekens JA
    Clin Cancer Res; 2006 Dec; 12(23):7054-8. PubMed ID: 17114213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine as third line therapy in patients with advanced colorectal cancer.
    Gubanski M; Naucler G; Almerud A; Lideståhl A; Lind PA
    Acta Oncol; 2005; 44(3):236-9. PubMed ID: 16076695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The utility of monitoring carcinoembyronic antigen during systemic therapy for advanced colorectal cancer.
    Grem JL; Steinberg SM; Chen AP; McAtee N; Cullen E; Hamilton JM; Allegra CJ
    Oncol Rep; 1998; 5(3):559-67. PubMed ID: 9538153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer.
    Gholam D; Giacchetti S; Brézault-Bonnet C; Bouchahda M; Hauteville D; Adam R; Ducot B; Ghémard O; Kustlinger F; Jasmin C; Lévi F
    Oncologist; 2006; 11(10):1072-80. PubMed ID: 17110626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced colorectal cancer with folinic acid and 5-fluorouracil in combination with cisplatinum.
    Sagaster P; Essl R; Teich G; Fritz E; Wasilewski M; Umek H; Dünser E; Mascher H; Micksche M
    Eur J Cancer; 1994; 30A(9):1250-4. PubMed ID: 7999407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.